TG Therapeutics Announces Upcoming Conference Call for Q3 2025

TG Therapeutics to Host Important Conference Call

On November 3, 2025, TG Therapeutics, Inc. (NASDAQ: TGTX) is gearing up to hold a significant conference call at 8:30 AM ET. This call presents a vital opportunity for stakeholders to delve into the company's financial performance for the third quarter of 2025. The session will be led by Michael S. Weiss, who serves as the Chairman and Chief Executive Officer of the company.

How to Join the Conference Call

Interested participants can join the conference call by dialing 1-877-407-8029 within the United States, or 1-201-689-8029 from outside the U.S. It is important to note that the conference title is "TG Therapeutics Earnings Call." For those who prefer to follow the discussion via the web, TG Therapeutics will also provide a live webcast, which can be accessed through the Events page in the Investors & Media section on their official website.

Replays Available After the Call

An audio recording will be available for individuals who may not be able to attend the live event. This recording will be accessible for 30 days post-call on the company's website, ensuring that all interested parties can catch up on the financial insights and strategies discussed.

Anticipated Financial Results Announcement

Prior to the conference call, TG Therapeutics plans to release a press statement outlining its financial results for the third quarter. This transparency aims to keep investors informed about the company’s current standings and future prospects.

Exploring TG Therapeutics' Mission

TG Therapeutics operates as an integrated biopharmaceutical company dedicated to developing innovative treatments targeting B-cell diseases. Their commitment to research and patient care is demonstrated through a robust pipeline featuring multiple investigational medicines. Notably, TG Therapeutics has achieved significant milestones, including the recent approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy). This product is designed for adult patients suffering from relapsing forms of multiple sclerosis, encompassing clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

International Approvals and Research Progress

Beyond its accomplishments within the United States, TG Therapeutics has also received regulatory approvals globally, allowing BRIUMVI to treat adult patients with active disease as defined by clinical or imaging characteristics. Such progress underscores their global reach and determination to enhance treatment options for B-cell disorders.

Engagement and Communication

For more information about TG Therapeutics' initiatives, investors and interested parties are encouraged to visit their website, where they might find additional insights and updates. Furthermore, following the company on various social media platforms will allow stakeholders to stay connected to the latest news and developments.

Frequently Asked Questions

What is the purpose of the conference call?

The conference call will discuss the financial results for Q3 2025 and provide insights into the future outlook of TG Therapeutics.

How can I participate in the conference call?

Participants can join by calling 1-877-407-8029 (U.S.) or 1-201-689-8029 (international) prior to the call scheduled for November 3, 2025.

Will there be a recording available after the call?

Yes, an audio recording of the call will be available on the company's website for 30 days following the event.

What is BRIUMVI®?

BRIUMVI® (ublituximab-xiiy) is a treatment approved for adults with relapsing forms of multiple sclerosis.

Who should I contact for more information?

For investor relations inquiries, you can reach out via email at ir@tgtxinc.com or contact media relations at media@tgtxinc.com.

About The Author

Even at just 28 years old, Lucas Young has made a name for himself as a writer and financial expert. Lucas is a gifted communicator of difficult financial ideas and has written a number of well-received books and articles that appeal to both new and experienced investors. The financial world has come to rely on his perceptive analysis and useful counsel. Many people have been enabled to make wise investment decisions by Lucas's commitment to financial literacy and his ability to demystify the complexities of the market. Lucas is still dedicated to advising and teaching people on their financial journeys as he shares his knowledge.

Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.